{"id":"peginterferon-alfa-2b-injection","safety":{"commonSideEffects":[{"rate":"70-90","effect":"Flu-like symptoms (fever, chills, fatigue)"},{"rate":"50-70","effect":"Headache"},{"rate":"40-60","effect":"Myalgia"},{"rate":"20-30","effect":"Depression"},{"rate":"10-20","effect":"Thrombocytopenia"},{"rate":"10-20","effect":"Neutropenia"},{"rate":"20-30","effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Peginterferon alfa-2b is a recombinant interferon alfa-2b conjugated with polyethylene glycol (PEG), which extends its half-life and duration of action. It activates natural killer cells, macrophages, and cytotoxic T lymphocytes, enhancing the body's immune response against viral infections and malignant cells. The pegylation allows for less frequent dosing compared to non-pegylated interferon alfa-2b.","oneSentence":"Peginterferon alfa-2b is a pegylated form of interferon alfa-2b that binds to interferon-alpha receptors on immune cells to enhance antiviral and anti-tumor immune responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:22:51.630Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis B"},{"name":"Chronic hepatitis C"},{"name":"Melanoma"},{"name":"Follicular lymphoma"}]},"trialDetails":[{"nctId":"NCT07445893","phase":"NA","title":"A Clinical Study of Gecacitinib Combined With Pegylated Interferon in Patients With PV","status":"NOT_YET_RECRUITING","sponsor":"Duan Minghui","startDate":"2026-02-24","conditions":"Polycythemia Vera (PV)","enrollment":30},{"nctId":"NCT06552429","phase":"PHASE2","title":"Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET","status":"RECRUITING","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2024-08-29","conditions":"Essential Thrombocythemia","enrollment":27},{"nctId":"NCT07231276","phase":"PHASE4","title":"Prospective Cohort Study on PEG-IFN-α-2b in Improving Clinical Cure Rate of Pediatric Patients With Chronic Hepatitis B","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2026-01-01","conditions":"HBV, Chronic Hepatitis B Virus","enrollment":113},{"nctId":"NCT07199413","phase":"PHASE1","title":"Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy: A Phase I Pilot Safety and Feasibility Study for Solid Tumor Patients With CNS Metastases","status":"NOT_YET_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2026-03-01","conditions":"Brain Metastases, Leptomeningeal Metastasis","enrollment":20},{"nctId":"NCT07183293","phase":"NA","title":"A Study on Peginterferon Alfa-2b Combined With NAs in Compensated HBV Cirrhosis","status":"NOT_YET_RECRUITING","sponsor":"Xiamen Humanity Hospital","startDate":"2025-10","conditions":"HBV-related Liver Cirrhosis","enrollment":30},{"nctId":"NCT06900166","phase":"PHASE4","title":"Pegylated Interferon Alfa-2b in Reducing Relapse Rates After Nucleos(t)ide Analogue Withdrawal in HBeAg-negative CHB Patients with Low Level HBsAg","status":"NOT_YET_RECRUITING","sponsor":"Huashan Hospital","startDate":"2025-04-01","conditions":"Chronic Hepatitis B","enrollment":360},{"nctId":"NCT06881056","phase":"NA","title":"Peginterferon α-2b Injection for Aerosol Therapy in Pediatric Respiratory Syncytial Virus Pneumonia","status":"RECRUITING","sponsor":"West China Second University Hospital","startDate":"2024-07-17","conditions":"Respiratory Syncytial Virus (RSV)","enrollment":90},{"nctId":"NCT06707922","phase":"NA","title":"A Follow-up Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B","status":"ENROLLING_BY_INVITATION","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2022-03-18","conditions":"Chronic Hepatitis B","enrollment":350},{"nctId":"NCT01353911","phase":"PHASE2","title":"Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-06-27","conditions":"Hepatitis C, Chronic","enrollment":368},{"nctId":"NCT01440595","phase":"PHASE2","title":"Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-11-28","conditions":"Hepatitis C, Chronic","enrollment":5},{"nctId":"NCT04846491","phase":"PHASE3","title":"A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2019-12-04","conditions":"Chronic Hepatitis B","enrollment":475},{"nctId":"NCT01180790","phase":"PHASE2","title":"Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2010-09","conditions":"Hepatitis C","enrollment":122},{"nctId":"NCT05988879","phase":"","title":"Functional Cure of Hepatitis B in HIV/HBV Co-infected Patients","status":"RECRUITING","sponsor":"Guangzhou 8th People's Hospital","startDate":"2023-08-02","conditions":"AIDS, Hepatitis B","enrollment":60},{"nctId":"NCT05922306","phase":"EARLY_PHASE1","title":"Efficacy of NA Combined With PEG-IFN-α2b in the Continuous Versus Pulsed Treatment of Patients With Chronic Hepatitis B","status":"RECRUITING","sponsor":"Anhui Medical University","startDate":"2023-07","conditions":"Hepatitis B, Chronic","enrollment":1084},{"nctId":"NCT05671315","phase":"NA","title":"A Prospective Study to Evaluate Peginterferon in Reducing the Incidence of HCC in CHB Patients","status":"RECRUITING","sponsor":"Qing XIe","startDate":"2019-07-03","conditions":"Chronic Hepatitis B, Intermediate to High Risk of HCC","enrollment":267},{"nctId":"NCT02634294","phase":"PHASE2, PHASE3","title":"Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT","status":"COMPLETED","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2015-08","conditions":"Hematological Neoplasms, Recurrence","enrollment":30},{"nctId":"NCT00573378","phase":"PHASE2","title":"Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia","status":"TERMINATED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2007-09","conditions":"Chronic Myeloid Leukemia","enrollment":12},{"nctId":"NCT02218164","phase":"PHASE2","title":"Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2014-08-12","conditions":"Squamous Cell Carcinoma of Skin, Carcinoma, Squamous Cell","enrollment":8},{"nctId":"NCT01678131","phase":"PHASE1","title":"Evaluating Fine Needle Aspiration to Measure Hepatic Vaniprevir (MK-7009) Concentrations in Participants With Chronic Hepatitis C (MK-7009-048)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-30","conditions":"Chronic Hepatitis C","enrollment":31},{"nctId":"NCT04943679","phase":"","title":"Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b Treatment in Patients With Advanced-Stage HCC","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-06-15","conditions":"Hepatocellular Carcinoma","enrollment":15},{"nctId":"NCT02343224","phase":"PHASE2","title":"Pegylated Interferon ALFA-2b in Children With Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas","status":"COMPLETED","sponsor":"Emory University","startDate":"2014-11","conditions":"Juvenile Pilocytic Astrocytomas, Optic Pathway Gliomas","enrollment":9},{"nctId":"NCT05203055","phase":"PHASE1, PHASE2","title":"Peginterferon Alpha-2b Therapy in Chronic Hepatitis Patients With Normal ALT Level and Low Viremia","status":"UNKNOWN","sponsor":"Fuzhou General Hospital","startDate":"2021-12-10","conditions":"Chronic Hepatitis B Patients With a Normal ALT Level and Low Viremia","enrollment":300},{"nctId":"NCT02112032","phase":"PHASE1","title":"Treatment of Advanced Melanoma With MK-3475 and Peginterferon","status":"COMPLETED","sponsor":"Hassane M. Zarour, MD","startDate":"2014-07-24","conditions":"Melanoma","enrollment":43},{"nctId":"NCT01710501","phase":"PHASE2","title":"A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-07","conditions":"Chronic Hepatitis C (CHC)","enrollment":87},{"nctId":"NCT00525031","phase":"PHASE2","title":"Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-08","conditions":"Melanoma","enrollment":55},{"nctId":"NCT00237484","phase":"PHASE3","title":"Effect of Infliximab on the Efficacy of Peg-Intron/Ribavirin in Patients With Hepatitis C (Study P04257AM4)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-07-18","conditions":"Hepatitis C, Chronic","enrollment":89},{"nctId":"NCT02174172","phase":"PHASE1","title":"A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-08-18","conditions":"Solid Cancers","enrollment":158},{"nctId":"NCT02379195","phase":"PHASE1, PHASE2","title":"Peginterferon and TIL Therapy for Metastatic Melanoma","status":"COMPLETED","sponsor":"Inge Marie Svane","startDate":"2014-11","conditions":"Metastatic Melanoma","enrollment":12},{"nctId":"NCT03547154","phase":"PHASE2, PHASE3","title":"Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"1998-10-22","conditions":"Chronic Myelogenous Leukemia","enrollment":344},{"nctId":"NCT03552549","phase":"PHASE2, PHASE3","title":"SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"1998-08-05","conditions":"Melanoma","enrollment":126},{"nctId":"NCT03554005","phase":"PHASE1","title":"Extended Administration of Polyethylene Glycol (PEG) Interferon Alfa-2b in Participants With Solid Tumors (C/I97-349/MK-4031-009)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"1997-12-29","conditions":"Neoplasms","enrollment":29},{"nctId":"NCT02247440","phase":"PHASE4","title":"HCV-HIV Co-infected Patient Cohort in Thailand","status":"COMPLETED","sponsor":"Institut de Recherche pour le Developpement","startDate":"2014-08","conditions":"Hepatitis C Infection, HIV","enrollment":18},{"nctId":"NCT03920605","phase":"NA","title":"Optimized Treatment of Peginterferon Alfa 2a/2b in Treatment Experienced Patients With HBV Related Liver Fibrosis","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2019-02-01","conditions":"Hepatitis B, Liver Fibrosis","enrollment":100},{"nctId":"NCT03919565","phase":"NA","title":"Optimized Treatment of Peginterferon Alfa 2a/2b in Anti-virus Treatment Naive Patients With HBV Related Liver Fibrosis","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2019-02-01","conditions":"Hepatitis B, Liver Fibrosis","enrollment":120},{"nctId":"NCT03537274","phase":"PHASE2, PHASE3","title":"Efficacy of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) Compared to Interferon Alfa-2B in Participants With Chronic Hepatitis C (MK-4031-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"1997-08-05","conditions":"Hepatitis C","enrollment":1224},{"nctId":"NCT01502696","phase":"PHASE3","title":"Adjuvant PEG Intron in Ulcerated Melanoma","status":"UNKNOWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2012-10","conditions":"Ulcerated Melanomas","enrollment":1200},{"nctId":"NCT03833362","phase":"PHASE3","title":"Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study)","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2014-05-07","conditions":"Hepatitis C","enrollment":420},{"nctId":"NCT00791271","phase":"PHASE1","title":"Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-09-02","conditions":"Melanoma","enrollment":17},{"nctId":"NCT00037882","phase":"PHASE2","title":"PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2001-02","conditions":"Leukemia, Myeloid, Philadelphia-Positive","enrollment":1},{"nctId":"NCT00415857","phase":"PHASE2","title":"Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-12","conditions":"Leukemia","enrollment":5},{"nctId":"NCT01758588","phase":"PHASE2","title":"Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2013-01","conditions":"Myelofibrosis","enrollment":8},{"nctId":"NCT01496807","phase":"PHASE1","title":"Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2012-02-17","conditions":"Melanoma","enrollment":31},{"nctId":"NCT00493805","phase":"PHASE4","title":"Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-04","conditions":"Hepatitis C, Chronic, Insulin Resistance","enrollment":59},{"nctId":"NCT00255034","phase":"PHASE4","title":"Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-02","conditions":"Hepatitis C, Chronic","enrollment":146},{"nctId":"NCT00371761","phase":"PHASE3","title":"PegIntron Versus Adefovir in the Treatment of Chronic Hepatitis B (CHB) e Antigen Positive Patients in Taiwan (P04498/MK-4031-278)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-09","conditions":"Hepatitis B, Chronic (CHB)","enrollment":25},{"nctId":"NCT00378599","phase":"PHASE3","title":"Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-05","conditions":"Liver Transplantation, Hepatitis C, Chronic, Liver Cirrhosis","enrollment":125},{"nctId":"NCT00686881","phase":"PHASE3","title":"Efficacy of Peginterferon Alfa-2b (SCH 054031) vs Glycyrrhizin in Interferon (IFN)-Treated Patients With Chronic Hepatitis C and F2/F3 Liver Fibrosis (P04773)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-12","conditions":"Hepatitis C, Chronic","enrollment":261},{"nctId":"NCT00255008","phase":"PHASE4","title":"Peg-Intron and Rebetol Therapy in Treatment of Naive Hepatitis C Patients: A Comparison of Race and Genotype on Treatment Outcome (Study P04212)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-03","conditions":"Hepatitis C, Chronic","enrollment":121},{"nctId":"NCT00202839","phase":"PHASE4","title":"Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-03","conditions":"Hepatitis C, Chronic","enrollment":160},{"nctId":"NCT00265395","phase":"PHASE3","title":"Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-12","conditions":"Hepatitis C, Chronic","enrollment":1428},{"nctId":"NCT00441584","phase":"PHASE3","title":"The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-07","conditions":"Hepatitis C, Chronic","enrollment":117},{"nctId":"NCT00761735","phase":"PHASE3","title":"5 Year Long-term Follow up in Pediatric Participants Who Received PegIntron Plus Rebetol in P02538 Part I (P02538 Pt 2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07","conditions":"Hepatitis C, Chronic","enrollment":94},{"nctId":"NCT00861406","phase":"PHASE1","title":"Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-03-10","conditions":"Melanoma","enrollment":38},{"nctId":"NCT01463956","phase":"PHASE2","title":"Efficacy of PegInterferon-Ribavirin-Boceprevir Therapy in Patients Infected With G1 HCV With Cirrhosis, Awaiting Liver Transplantation","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2012-01-06","conditions":"HCV Infection, Liver Cirrhosis, Experimental","enrollment":58},{"nctId":"NCT01949805","phase":"PHASE3","title":"Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera","status":"COMPLETED","sponsor":"AOP Orphan Pharmaceuticals AG","startDate":"2013-09","conditions":"Polycythemia Vera","enrollment":257},{"nctId":"NCT02973646","phase":"PHASE4","title":"Peginterferon Alfa-2b Treatment in HBeAg(+) Chronic Hepatitis b Patients Based on Interferon Gene Mutation and Receptor Detection","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2016-01","conditions":"Chronic Hepatitis b","enrollment":100},{"nctId":"NCT01838772","phase":"PHASE4","title":"HCV Treatment in HIV Co-Infected Patients in Asia","status":"COMPLETED","sponsor":"amfAR, The Foundation for AIDS Research","startDate":"2013-12","conditions":"Hepatitis C, HIV","enrollment":188},{"nctId":"NCT01701063","phase":"PHASE1, PHASE2","title":"An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus","status":"TERMINATED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2013-01","conditions":"Hepatitis C","enrollment":42},{"nctId":"NCT00723931","phase":"","title":"PegIntron Injection Surveillance Plan (Study P04123)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-06","conditions":"Hepatitis C, Chronic","enrollment":1267},{"nctId":"NCT00723892","phase":"","title":"Adherence in Patients Receiving PegIntron/Rebetol for Hepatitis C in Conjunction With a Psychotherapy Support Program (Study P04252)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-07","conditions":"Hepatitis C, Chronic, Hepacivirus","enrollment":614},{"nctId":"NCT02204475","phase":"PHASE3","title":"Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-11","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT00725205","phase":"","title":"Patient Compliance During PegIntron and Rebetol Combination Therapy in Chronic Hepatitis C (Study P04690)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-03","conditions":"Hepatitis C, Chronic, Hepatitis C","enrollment":294},{"nctId":"NCT00705224","phase":"","title":"Effect of Insulin Resistance on the Safety and Efficacy of Pegylated Interferon and Ribavirin Treatment in HCV (Study P05562)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-05","conditions":"Hepatitis C, Chronic, Hepatitis C Virus","enrollment":250},{"nctId":"NCT00724295","phase":"","title":"Safety and Efficacy of PegIntron and Rebetol Combination Therapy in Patients With Chronic Hepatitis C in Japan (Study P04505)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-04","conditions":"Hepatitis C, Chronic, Hepatitis C","enrollment":1077},{"nctId":"NCT00724230","phase":"","title":"Safety and Efficacy of PegIntron Plus Rebetol in Patients With Chronic Hepatitis C in Japan, Excluding (1) Subjects With HCV Genotype 1 and High Viral Load, and (2) Interferon-naïve Subjects With Low Viral Load (Study P04841)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-02","conditions":"Hepatitis C, Chronic, Hepatitis C","enrollment":505},{"nctId":"NCT01335529","phase":"PHASE2","title":"Boceprevir in HIV-HCV Coinfected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2011-05","conditions":"HCV Coinfection, HIV-1 Infection","enrollment":69},{"nctId":"NCT00018031","phase":"PHASE2","title":"Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2001-06","conditions":"Hepatitis C, HIV Infections","enrollment":36},{"nctId":"NCT00323804","phase":"PHASE2, PHASE3","title":"Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2006-05","conditions":"Hepatitis C, Chronic, Liver Fibrosis","enrollment":372},{"nctId":"NCT00528528","phase":"PHASE2","title":"An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants","status":"COMPLETED","sponsor":"Tibotec BVBA","startDate":"2007-10","conditions":"Chronic Hepatitis C","enrollment":166},{"nctId":"NCT01290679","phase":"PHASE3","title":"An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2011-03","conditions":"Hepatitis C","enrollment":393},{"nctId":"NCT01366638","phase":"PHASE3","title":"A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2011-05","conditions":"Hepatitis C, Chronic","enrollment":79},{"nctId":"NCT01949168","phase":"PHASE2","title":"A Pilot Study of Boceprevir for the Treatment of Genotype 6 HCV","status":"UNKNOWN","sponsor":"St Vincent's Hospital Melbourne","startDate":"2013-09","conditions":"Chronic Hepatitis C","enrollment":30},{"nctId":"NCT00588146","phase":"PHASE2","title":"Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2007-01","conditions":"Anemia, Liver Disease, Hypoxemia","enrollment":10},{"nctId":"NCT00367887","phase":"PHASE2","title":"A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-10","conditions":"Hepatitis C","enrollment":246},{"nctId":"NCT01374308","phase":"PHASE3","title":"NASVAC Phase-III Trial in Chronic Hepatitis B (CHB) Patients","status":"UNKNOWN","sponsor":"Clinical Research Organization, Dhaka, Bangladesh","startDate":"2011-06","conditions":"Chronic Hepatitis B","enrollment":160},{"nctId":"NCT00502099","phase":"PHASE4","title":"Comparison of Pegasys Versus Peg-Intron for Treatment of Chronic Hepatitis C Genotype 4","status":"COMPLETED","sponsor":"Amr Hafez","startDate":"2006-01","conditions":"Hepatitis C","enrollment":217},{"nctId":"NCT00446134","phase":"PHASE2","title":"Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (HCV)","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2007-03","conditions":"Chronic Hepatitis C","enrollment":278},{"nctId":"NCT00593151","phase":"PHASE1, PHASE2","title":"Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Biolex Therapeutics, Inc.","startDate":"2008-01","conditions":"Hepatitis C","enrollment":32},{"nctId":"NCT00863239","phase":"PHASE2","title":"Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCV","status":"COMPLETED","sponsor":"Biolex Therapeutics, Inc.","startDate":"2009-03","conditions":"Hepatitis C, Chronic","enrollment":116},{"nctId":"NCT00953589","phase":"PHASE2","title":"480 STUDY: Phase 2b Study of Locteron Plus Ribavirin to Treat Hepatitis C Virus (HCV)","status":"COMPLETED","sponsor":"Biolex Therapeutics, Inc.","startDate":"2009-07","conditions":"Hepatitis C, Chronic","enrollment":74},{"nctId":"NCT00047879","phase":"PHASE2","title":"Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2002-10","conditions":"Glioma","enrollment":7},{"nctId":"NCT00886457","phase":"PHASE1","title":"5-aza-2-deoxycytidine With Pegylated Interferon-alfa 2B: A Phase I Study With Molecular Correlates","status":"TERMINATED","sponsor":"Nevada Cancer Institute","startDate":"2009-04","conditions":"Cancer","enrollment":3},{"nctId":"NCT01325896","phase":"PHASE2","title":"Maintenance Treatment of Multiple Myeloma (MM) After Autologous Peripheral Blood Transplant (PBSCT) Using Polyethylene Glycol alpha2B Interpheron (PEG-INTRON)","status":"UNKNOWN","sponsor":"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","startDate":"2002-09","conditions":"Multiple Mieloma","enrollment":33},{"nctId":"NCT00351403","phase":"PHASE4","title":"Individually Adapted Therapy Duration for the Treatment of Chronic Hepatitis C Genotype 1 Infection","status":"COMPLETED","sponsor":"FGK Clinical Research GmbH","startDate":"2006-07","conditions":"Hepatitis C, Chronic","enrollment":390},{"nctId":"NCT00059358","phase":"PHASE1, PHASE2","title":"Zidovudine Levels in HIV Infected Patients Being Treated for HCV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2001-09","conditions":"HIV Infections, Hepatitis C","enrollment":16},{"nctId":"NCT00277758","phase":"PHASE1","title":"Safety Study of Low Dose Interleukin 2 (IL-2) Plus PEG-IFN/RBV In Chronic Hepatitis C Virus Genotype I","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2004-03","conditions":"Hepatitis C","enrollment":18}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"HEPATIC CIRRHOSIS"},{"count":1,"reaction":"ABDOMINAL DISTENSION"},{"count":1,"reaction":"ADHESION"},{"count":1,"reaction":"AGITATION"},{"count":1,"reaction":"ANAEMIA"},{"count":1,"reaction":"ATAXIA"},{"count":1,"reaction":"BILIARY TRACT DISORDER"},{"count":1,"reaction":"BLOOD THYROID STIMULATING HORMONE INCREASED"},{"count":1,"reaction":"CARDIOMYOPATHY"},{"count":1,"reaction":"CHILLS"}],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Peginterferon alfa-2b Injection","genericName":"Peginterferon alfa-2b Injection","companyName":"Nanfang Hospital, Southern Medical University","companyId":"nanfang-hospital-southern-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Peginterferon alfa-2b is a pegylated form of interferon alfa-2b that binds to interferon-alpha receptors on immune cells to enhance antiviral and anti-tumor immune responses. Used for Chronic hepatitis B, Chronic hepatitis C, Melanoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}